Bryan Garnier - Novo Nordisk (novob) NOVO NORDISK: Semaglutide 2.0mg and tirzepatide both beat Ozempic: what’s now ? | BUY | DKK505(-2%)

Report

Bryan Garnier

Eric Le Berrigaud

NOVO NORDISK: Semaglutide 2.0mg and tirzepatide both beat Ozempic: what’s now ? | BUY | DKK505(-2%)

NOVO NORDISK - BUY | DKK505(-2%)
Semaglutide 2.0mg and tirzepatide both beat Ozempic: what’s now ?

Data from SUSTAIN FORTE presented at ADA congress
Tirzepatide is also superior to Ozempic, but to semaglutide 2.0mg too?
Are dual agonists the future standard among GLP-1 compounds?

28/06/2021 3 EN

Underlying

Novo Nordisk

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Le Berrigaud

Other Reports on these Companies

New Street Research

Novo - Wegovy Stockpiling Almost $5bn (BUY, TP DKK1100, 5 pgs)

Our latest analysis shows that Novo could drive material consensus upgrades by starting to release a potential ~$5bn Wegovy stockpile. With Novo restricting Wegovy supply between Nov-21 & Dec-22, and then from May-23 onwards, they have built up a substantial stockpile of product, in our view. Our analysis of their inventory shows there is likely as much as $5bn of finished or close-to-finished Wegovy product at current US net prices. Our analysis of the supply chain and distribution strategy explains why Novo have retained such large inventories. We believe that Novo can produce consensus esti...

EUR 4659.00

April 10, 2024 April 10, 2024 1 EN

New Street Research

Novo - 8 Reasons It’s Going to DKK1100 (BUY, TP DKK1100 [850], 18 pgs)

Novo are just too good to bet against. We now increase our 2030 obesity franchise sales to $50bn and most importantly show that sema’ is only 27% of group sales in 2031. Therefore, if sema’ sales halve by 2034, it’s only a ~5% p.a. headwind to group sales 2032-34. Greater visibility on the post-sema outlook is a strong reason for the Novo multiple to be retained into 2025. We see 8 reasons why Novo will hit DKK1100 in the next year, driven by EPS upgrades, increased supply & P3 readouts. We see upside beyond DKK1100 from osteoarthritis & AD. We are 8% ahead of consensus 2025 EBIT & 10% in 2028...

EUR 4659.00

March 13, 2024 March 13, 2024 1 EN

New Street Research

EU Pharma - 2024 Year Ahead (28 pgs)

For EU Pharma, 2024 is likely to be characterised by EPS revisions, a handful of new launches & sluggish EPS growth for a number of names. The relative lack of pipeline catalysts makes forecasting sales and EPS much more important than for 2023. We identify 4 key issues to watch for: 1) Medicaid AMP cap removal, 2) Higher tax costs, 3) Higher debt costs & 4) a handful of very specific company issues that could make a material difference to performance (Novo: Wegovy supply, GSK: litigation, SAN: tolebrutinib P3). Our top pick is Novo, we upgrade Sanofi to BUY & see more catalysts than the marke...

EUR 4659.00

December 18, 2023 December 18, 2023 1 EN

Onward: Model Update

We update our financial model after Onward medical released FY 2023 results last week The rating remains unchanged with a Buy recommendation and EUR 20 PT.

7h / 36m 7h / 36m 1 EN

Cedric Rossi

Cedric Rossi

Hugo Boss: Weak China and month of April spoilt the mood

In our view, the sharp negative market reaction was triggered by subdued trends in China and April trends which were slightly below the Q1 top-line performance (+6% FX-n), on top of another tough comparison base (Q2 2023: +20% FX-n). Whilst FY24 outlook was reiterated, management's relatively cauti

8h / 24m 8h / 24m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis reports Q1, on track with US trial

Egetis reported Q1 2024 results with an operating loss of SEK (68.6m) and a cash position of SEK 251.7m. In the pipeline, the most important update has been to the status of the critical US phase 3 trial, where the company reported that 13/16 patients have been recruited, whereof 6 patients have co

8h / 24m 8h / 24m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

NOVO NORDISK: Semaglutide 2.0mg and tirzepatide both beat Ozempic: what’s now ? | BUY | DKK505(-2%)

Novo - Wegovy Stockpiling Almost $5bn (BUY, TP DKK1100, 5 pgs)

Novo - 8 Reasons It’s Going to DKK1100 (BUY, TP DKK1100 [850], 18 pgs)

EU Pharma - 2024 Year Ahead (28 pgs)

Onward: Model Update

Hugo Boss: Weak China and month of April spoilt the mood

Egetis reports Q1, on track with US trial

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe